Find Oncology Drugs in Phase III Clinical Development in CHINA

Lead Product(s): Pamiparib

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The global Phase 3, is designed to compare the efficacy and safety of pamiparib to placebo as maintenance therapy in approximately 540 patients with advanced gastric cancer.

Lead Product(s): tislelizumab,Carboplatin,Paclitaxel

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

Based on the pre-planned interim analysis, both tislelizumab treatment arms crossed the pre-specified efficacy boundary compared to chemotherapy alone.

Lead Product(s): Bevacizumab

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Coherus BioSciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Coherus will commercialize Innovent’s biosimilar candidate to Avastin® (bevacizumab) in the United States and Canada.

Lead Product(s): Sintilimab,Pemetrexed,Platinum

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 12, 2020

Details:

Based on the interim analysis, sintilimab in combination with ALIMTA and platinum demonstrated a statistically significant improvement in PFS compared with placebo with ALIMTA and platinum combo.

Lead Product(s): CS1001,Fluorouracil,Cisplatin

Therapeutic Area: Oncology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

The GEMSTONE-304 trial is a multicenter clinical study designed to evaluate the efficacy and safety of CS1001 in combination with 5-fluorouracil plus cisplatin (FP) doublet chemotherapy.